Previous 10 | Next 10 |
home / stock / bovnf / bovnf news
Agreement covers Phase 1/2a trial with TNFR2 agonist antibody BI-1910 First data from BI-1910 single agent arm expected by YE 2024 LUND, SWEDEN / ACCESSWIRE / April 2, 2024 / BioInvent International AB ("BioInvent") (STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the di...
LUND, SE / ACCESSWIRE / February 20, 2024 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) invites investors, analysts, and the press to a presentation of the year-end report 2023 at 2:00 pm on February 22. The report will be published at 8:00 am CET the same day. BioInvent's ...
LUND, SWEDEN / ACCESSWIRE / February 9, 2024 / BioInvent International (STO:BINV) Clinical supply agreement with AstraZeneca to support Phase 1/2a BI-1206 combination study BI-1206 to be evaluated in combination with Calquence® and rituximab in Phase 1/2a trial in non-Hodgkin's lympho...
Full rights returned following Exelixis' corporate restructuring announced January 07, 2024 Collaboration generated novel targets and antibodies for use in immuno-oncology therapeutics LUND, SWEDEN / ACCESSWIRE / January 12, 2024 / BioInvent International (STO:BINV) BioInvent Internati...
Data from seven different clinical studies expected throughout the year, including combination data for the two lead programs BI-1808 and BI-1206 in H1/mid-2024 Well-financed with 1358 SEK million (~USD 132M), as of September 30, 2023 LUND, SE / ACCESSWIRE / January 4, 2024 / BioInvent ...
LUND, SWEDEN / ACCESSWIRE / December 5, 2023 / BioInvent International (STO:BINV) Phase 1 data from 18 patients treated with BI-1607 in combination with trastuzumab presented at San Antonio Breast Cancer Symposium BI-1607 well tolerated with no serious adverse events, at doses of 75-900mg...
Trial investigates BI-1910 as single agent and in combination with pembrolizumab Exploratory expansion cohorts planned in hepatocellular carcinoma and non-small cell lung cancer BioInvent now has five drug candidates in six clinical trials, reflecting productivity of technology platform...
LUND, SE / ACCESSWIRE / November 3, 2023 / BioInvent International (STO:BINV): Preliminary data from Phase 1 part show encouraging early efficacy signals Robust partial response in one patient with gastrointestinal tumor; 7 cases of stable disease Favorable safety profile with no dose-...
Broad anti-tumor activity in preclinical studies, activating T cells and NK cells FcyR-independent antitumor activity Data support start of Phase 1 trial in H2 2023, further expanding BioInvent's pipeline LUND, SE / ACCESSWIRE / October 31, 2023 / ("BioInvent") (Nasdaq Stockholm:B...
LUND, SE / ACCESSWIRE / October 26, 2023 / BioInvent International (STO:BINV) "In the third quarter of 2023, BioInvent achieved a significant landmark with the recruitment of the first patient to the BI-1808 single agent Phase 2a study. BI-1808 can potentially become a novel checkpoint inhibi...
News, Short Squeeze, Breakout and More Instantly...
Model-informed approach supporting dose selection and optimization of clinical development Confirming wide potential dose-range of BI-1808 in the continued clinical evaluation which already has shown promising single agent safety and efficacy Poster to be presented at PAGE 2024 to be ...
LUND, SWEDEN / ACCESSWIRE / June 24, 2024 / BioInvent International AB ("BioInvent") (STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that the China Nat...
BioInvent International (STO:BINV) Discussion on TNFR2 and FcyRIIB as promising targets in immuno-oncology on June 18, 2024 LUND, SWEDEN / ACCESSWIRE / May 30, 2024 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development...